The wait on the future announcements with this company is very frustrating, especially after Eric Adams all but declared the name of the future CMO. I know this step is important in bringing forward the drug platform, but feel the wait has been too long for the clinical trials for EB.
This keeps me going... from Inmed website.
Successes and Future Applications
We have successfully constructed the terpenoid biosynthetic pathway and the gateway pathway for synthesis of CBGA and the downstream pathways for synthesis of THCA and CBDA. Our proprietary pathway is significantly more productive than previously patented terpenoid pathways, and we have confirmed the biosynthesis of the cannabinoids using validated HPLC methodologies and 1H-NMR instrumentation.
We have constructed a series of E. coli strains that express variations and/or subsets of the entire biosynthetic pathway and have tested production in lab-scale fermentation tanks. Next steps in the biosynthesis program are to:
continue efforts to further diversify the number of cannabinoids produced using InMed’s system;
scale-up the biosynthesis process to larger vessels, where protocols will be developed to optimize manufacturing parameters; and
identify external vendors to assist in the commercial scale-up of the process.
Options for InMed’s GLP and GMP product manufacturing include either (1) building a dedicated biosynthesis facility or (2) transferring our process/know-how to a contract manufacturing organization with existing infrastructure to produce for us the preclinical, clinical and commercial scale supply of our product candidates.
In addition to providing a source of raw materials (active pharmaceutical ingredients, or “API”) for InMed’s therapeutic products, our biosynthesis program may play a significant role as a source of raw materials to other pharmaceutical companies, as well as a number to a number of other industries outside of the pharmaceutical segment.
The role of THC and CBD continues to expand at an exceptional rate in the recreational, nutraceutical and ‘medical marijuana’ spaces, where biosynthesis may prove to be an economical alternative to plant-sourced products. According to an October 2016 report issued by the Hemp Business Journal, the total consumer market for CBD alone is expected to surpass $2.1 billion by 2020, up from only $90 million in 2015. Estimates for the medical use of marijuana (delivering THC and CBD from the plant via smoking) have been estimated to be $12 billion in 2016 by Visiongain Ltd. and is expected to surpass $55 billion by 2025, according to a 2017 report by Grandview Research, Inc.
